FDA grants Fast Track to T-cell engager VIR-5500 for prostate cancer
FDA action · Business Wire · 2026-10-08. Number 3 in the UrologyWatch Top 5 for October 11, 2026.
VIR-5500, a dual-masked T-cell engager, received FDA Fast Track designation for prostate cancer, which may expedite its development and review.
Why it matters: Signals an emerging class of engineered immunotherapies entering the mCRPC pipeline alongside PSMA radioligand and bispecific approaches.
Source: Business Wire
Loading today's edition…